Pakistan Pharmaceuticals and Healthcare Report Q2 2009

Publication Date	April 2009
Publisher	Business Monitor
Product Type	Report
Pages	73
ISBN Number	not applicable
Product Code	BMI03690

Buy this product or for assistance call +44 20 7060 7474

PDF £250.00$416 | €280

FAX Order above formats by FAX

Summary

The value of Pakistan's pharmaceutical market is forecast to reach US$3.34bn by 2013, representing a compound annual growth rate (CAGR) of 10.55%. This rate of expansion is one of the highest in our coverage universe. However, it is at significant risk due to the escalation of political unrest and terrorist activity in Pakistan. A downgrade is very likely in the Q309 update of this report. Combined sales of generic drugs, patented products and over-the-counter (OTC) medicines were calculated to be US$2.02bn in 2008.

During February 2009, Khawaja Shah-zeb Akram, vice chairman of Pakistan's Industrial and Traders Associations Front (PIAF), stated that the government should take significant steps to support domestic pharmaceutical companies. He also added that the pharmaceutical sector has the capability to generate huge revenue through exports if the state promotes a business-friendly environment.

Prices of pharmaceuticals sold in Pakistan are determined by an advisory committee in the Ministry of Health (MoH). The body uses a system of 'price mechanism' and 'standard formula', which takes input costs into account. However, it appears that this approach is not working. Some drug-makers have unilaterally increased the prices of their products following hikes in the cost of raw materials, fuel and electricity, and the depreciation of the rupee.

Regulations are in place but frequently not adhered to. For example, it was revealed in December 2008 that only a fifth of drug-makers in Lahore were destroying their waste - such as expired medicines and toxic raw materials - in incinerators. They were therefore infringing the Hospital Waste Management Rules (HWMR).

During January 2009, the government of Punjab in Pakistan was planning to put into effect Drug Rules 2009 in order to curtail counterfeit drugs. As per the Drug Act of 1976, wholesalers were not given any place in the drug supply chain. However, in the new Drug Rules 2009, wholesalers are given a place with the condition that they will be held accountable if counterfeit drugs are found with the retailers they supply.

Content

Executive Summary
Pakistan Pharmaceutical Industry SWOT
Pakistan Political SWOT
Pakistan Economic SWOT
Pakistan Business Environment SWOT
Pharmaceutical Business Environment Ratings
Business Environment Ranking
Limits Of Potential Returns
Risks To Realisation Of Returns
Market Summary
Regulatory Regime
Intellectual Property Regime
Shortcomings of The Intellectual Property Environment
Counterfeit Drugs
Pricing and Reimbursement Regime
Recent Pricing and Reimbursement Developments
Industry Trends And Developments
Epidemiology
Healthcare System
Pharmaceutical Sector
Traditional Medicine
Research and Development
Retail Sector
International Co-operation
Medical Devices
Industry Forecast Scenario
Overall Market Forecast
Key Growth Factors - Industry
Key Growth Factors - Macroeconomic
Prescription Market Forecasts
OTC Market Forecast
Patented Product Market Forecast
Generic Drug Market Forecast
Export/Import Forecasts
Other Healthcare Data Forecasts
Key Risks To BMI's Forecast Scenario
Competitive Landscape
Recent Pharmaceutical Industry Developments
Company Profiles
Leading Multinational Manufacturers
GlaxoSmithKline
Pfizer
Abbott Laboratories
Novartis
Sanofi-Aventis
Merck & Co
Wyeth
Domestic Manufacturers
Hilton Pharma
Efroze Chemical Industries
Ferozsons Laboratories
Pacific Pharmaceuticals
Country Snapshot: Pakistan Demographic Data
Section 1: Population
Section 2: Education and Healthcare
Section 3: Labour Market And Spending Power
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Weighting
Sources
List of Tables
- Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q209
- Table: Healthcare And Pharmaceutical Companies That Are Members Of The American Business Council Of Pakistan
- Table: Pakistan - Key Healthcare Statistics, 2007 ('000 people, unless otherwise stated)
- Table: Pakistan - Drug Expenditure Indicators, 2003-2013
- Table: Pakistan - Health Expenditure Indicators, 2003-2
- Table: Pakistan - Economic Activity
- Table: Pakistan - Prescription Market Indicators, 2003-2013 (PKRmn unless otherwise stated)
- Table: Pakistan - OTC Drugs Market Indicators, 2003-2013 (PKRmn unless otherwise stated)
- Table: Pakistan - Patented Drugs Market Indicators, 2003-2013
- Table: Pakistan - Generic Drugs Market Indicators, 2003-2013
- Table: Pakistan - Pharmaceutical Trade Indicators, 2003-2013 (US$mn)
- Table: Pakistan - Other Healthcare Indicators, 2003-2013 (per '000 population, unless otherwise stated)
- Table: Pakistan's Pharmaceutical Market In Q406
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Manufacturing Wages, 2000-2012
- Table: Pharmaceutical Business Environment Indicators
- Table: Weighting Of Components